A5061109021- Psoriasis: Treatment and Pathogenesis
- Spondyloarthritis Studies and Treatments
- Autoimmune and Inflammatory Disorders Research
- Infectious Diseases and Tuberculosis
- Actinomycetales infections and treatment
- Macrophage Migration Inhibitory Factor
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Inflammasome and immune disorders
- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Gout, Hyperuricemia, Uric Acid
- Pharmacological Effects of Natural Compounds
- Soft tissue tumors and treatment
- Orthopedic Infections and Treatments
- Complement system in diseases
- Case Reports on Hematomas
- Parkinson's Disease and Spinal Disorders
- Dermatology and Skin Diseases
- Herpesvirus Infections and Treatments
- Autoimmune Neurological Disorders and Treatments
- Hematological disorders and diagnostics
- Inflammatory Bowel Disease
- Therapeutic Uses of Natural Elements
- Urticaria and Related Conditions
- IL-33, ST2, and ILC Pathways
Institut Pasteur
2016-2023
Université Paris Cité
2016-2023
Délégation Paris 7
2020-2023
Sorbonne Paris Cité
2020-2023
Université d'Angers
2023
Sorbonne Université
2021-2022
Assistance Publique – Hôpitaux de Paris
2016-2022
Inserm
2016-2022
Hôpital Cochin
2016-2022
Centre Hospitalier Universitaire d'Angers
2022
Objective The importance of interleukin‐17A (IL‐17A) in the pathogenesis axial spondyloarthritis (SpA) has been demonstrated by success IL‐17A blockade. However, nature cell populations that produce this important proinflammatory cytokine remains poorly defined. We undertook study to characterize major IL‐17A–producing blood peripheral patients with SpA, a focus on mucosal‐associated invariant T (MAIT) cells, population known be capable producing IL‐17. Methods evaluated production from 5...
Objectives Antitumour necrosis factor (TNF) therapy has revolutionised treatment of several chronic inflammatory diseases, including spondyloarthritis (SpA). However, TNF inhibitors (TNFi) are not effective in all patients and the biological basis for failure remains unknown. We have analysed induced immune responses to define mechanism action blockers SpA identify immunological correlates responsiveness TNFi. Methods Immune microbial pathway-specific stimuli were peripheral blood samples...
Objective The objective of this study was to assess the safety and efficacy abatacept in patients with SLE refractory conventional treatment routine clinical practice. Methods This retrospective included 11 treated for an active disease. primary endpoint change Disease Activity Index (SLEDAI) score at six months. Response defined as a decrease SLEDAI ≥4 patient continuing abatacept. Results Indications were articular ( n=8), renal n=1) cutaneous involvement autoimmune thrombocytopenia n=1)....
Abstract In spondyloarthritis, little is known about the relation between circulating cytokines and patient phenotype. We have quantified serum levels of T helper type 1 cell (Th1), Th2 Th17 in patients with recent-onset axial spondyloarthritis (AxSpA) from DESIR cohort, a prospective, multicenter French cohort consisting 708 inflammatory back pain (duration >3 months but <3 years) suggestive AxSpA. Serum Th1, Th2, were assessed at baseline fulfilling ASAS criteria (ASAS+) compared...
Systemic-onset JIA (SJIA) and adult-onset Still's disease (AOSD) are the same sporadic systemic auto-inflammatory disease. SpA is a group of inflammatory non-autoimmune disorders. We report observations eight patients with SJIA/AOSD who also presented features during their evolution estimate prevalence in SJIA/AOSD.This was retrospective national survey departments paediatric adult rheumatology internal medicine. To be included, SJIA had to fulfil ILAR criteria, AOSD Yamaguchi or Fautrel all...
<h3>Background</h3> IL-17A-inhibition has been very successful in AxSpA but the cell populations targeted by this new therapeutic remain unknown. This question is relevant because recent failure of anti-IL-23 demonstrated that IL-23-independent IL-17-producing cells may be particular relevance for SpA pathogenesis. Some data from literature suggests involvement MAIT, γδ T, and neutrophils as IL-17A producing (1–3). However, even though they responsible IL-17A-mediated inflammation, it still...
The coronavirus disease 2019 (COVID-19) pandemic has accelerated changes to rheumatology daily clinical practice. main goal of the 12th International Immunology Summit, held 25-26 June, 2021 (virtual meeting), was provide direction for these active rather than undergoing change reactively in order improve patient outcomes. This review describes and explores concept practice based on presentations from Summit. Many brought about by COVID-19 may be considered as having a positive impact...
<h3>Background</h3> IL-31 is a newly-described cytokine mainly produced by activated Th2 cells. acts through IL31-RA and oncostatin heterodimeric receptors that activate STAT3 STAT5. So far, IL31 has been involved in airway hypersensitivity atopic dermatitis. More recent data suggest its involvement psoriasis, inflammatory bowel disease osteoporosis. <h3>Objectives</h3> We aimed to assess serum levels patients with onset axial spondyloarthritis (SpA) from DESIR cohort. <h3>Methods</h3> The...
<h3>Background</h3> The etiology of spondyloarthritis (SpA) is unknown but seems to indicate a link between genetic and environmental factors. Many GWAS studies demonstrated strong association IL23R gene the disease. Moreover, several IL-17 producing lymphocyte populations characterized by expression CCR6 (TD4+, TCD8, Tγδ ILC) are involved in pathophysiolgy SpA. <h3>Objectives</h3> aim study was identify cells population disease development: - By comparing simultaneously TCD4+, TCD8+, et ILC...
<h3>Background</h3> IL-17A inhibitors (IL-17i) and TNF-inhibitors (TNFi) are currently the only biologic drugs available as first line treatment in axial spondyloarthritis (axSpA). While several studies have provided mechanistic insights into TNFi action, much less is known how IL-17i affect immune responses patients. <h3>Objectives</h3> We compared effects of on cell frequencies induced to obtain information about mechanisms action these two axSpA patients <i>in vivo</i>. <h3>Methods</h3>...
Background: It is currently not known if TNF or IL-17A inhibitors have an impact on immune cell frequencies in axial Spondyloarthritis (AxSpA). This question important to understand the of biologics system. Data from clinical trials didn’t show significant modification cells and especially lymphocytes. But regarding risk infections linked these treatments lymphocyte subsets are certainly disturbed. Moreover, could affect with unusual phenotype. Objectives: To identify phenotype affected by...